The aim of this study was to investigate the prevalences of plasmid-mediated AmpC ␤-lactamases (PABLs) in isolates of Escherichia coli and Klebsiella spp. from a university hospital in China. A total of 1,935 consecutive nonrepeat clinical isolates of Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca were collected between January 2003 and July 2005. The isolates with cefoxitin zone diameters less than 18 mm (screen positive) were selected for PCR of the bla AmpC genes and sequencing. Fifty-four (2.79%) isolates harbored PABLs, as demonstrated by PCR and isoelectric focusing. Sequence analysis revealed the presence of bla DHA-1 and bla CMY-2 genes. The Southern blot hybridization studies confirmed that bla CMY-2 and bla DHA-1 were located on plasmids. Based on species, PABLs were detected in 4.29% (29 isolates of DHA-1 and 1 isolate of CMY-2) of K. pneumoniae, 1.91% (11 isolates of DHA-1 and 12 isolates of CMY-2) of E. coli, and 3.03% (1 isolate of DHA-1) of K. oxytoca isolates. In contrast to our anticipation, the occurrence rate of DHA-1-producing K. pneumonia significantly decreased (P < 0.01), from 7.54% in 2003 to 2.72% in 2004. The results of random amplified polymorphic DNA analysis indicate that the prevalences of DHA-1-producing K. pneumoniae and CMY-2-producing E. coli strains were not due to epidemic strains. In conclusion, DHA-1 was the most prevalent acquired AmpC beta-lactamase in this collection of isolates from a medical center in China, and DHA-1-producing K. pneumoniae was the most prevalent bacterium harboring a PABL. To the best of our knowledge, this is the first report of CMY-2-type AmpC ␤-lactamases in the Chinese mainland.
Plasmid-mediated AmpC ␤-lactamases (PABLs) are derived from chromosomal ampC genes of the family Enterobacteriaceae, such as those of Citrobacter freundii, Enterobacter cloacae, and Aeromonas species.
PABLs have been reported to occur in the United States, Korea, Japan, etc. (4, 14, 24) , but there are seldom data indicating PABLs in the Chinese mainland (28, 29) . The aims of this study were to establish the prevalence rate of this resistance mechanism in isolates of Klebsiella pneumoniae, Klebsiella oxytoca, and Escherichia coli from a university hospital in Shanghai, China. The first identification of the CMY-2 AmpC ␤-lactamase in the Chinese mainland is also described.
MATERIALS AND METHODS

Bacterial isolates.
A total of 1,935 nonduplicate clinical isolates of Escherichia coli (n ϭ 1,203), Klebsiella pneumoniae (n ϭ 699), and Klebsiella oxytoca (n ϭ 33) were consecutively selected from the Sixth Affiliate Hospital of Shanghai Jiao Tong University between January 2003 and July 2005. Positive controls were used, including Klebsiella pneumoniae (strain MISC 304, containing MIR-1) and clinical isolates of C. freundii, E. cloacae, Hafinia alvei, and Morganella morganii. Identification was performed by the GNI card of the Vitek system (BioMèrieux, MO) or Walk Away 40 (Dade-Bering, Sacramento, CA).
Antimicrobial susceptibility testing and screening of ␤-lactamases. Isolates were tested for susceptibility by the standard disk diffusion method, and the results were interpreted according to the guidelines of the CLSI (formerly NCCLS). Isolates with cefoxitin zone diameters less than 18 mm (4) were considered positive for the AmpC ␤-lactamase screening test and were selected for MIC, isoelectric focusing (IEF), PCR, and sequencing analyses. The MICs and the presence of extended-spectrum ␤-lactamases (ESBLs) were determined by using the ESBL confirmation panel (Dade-Behring, Sacramento, CA). The presence of ESBLs was also investigated by the CLSI-recommended disk screening and confirmatory tests.
PCR and sequencing. Multiplex PCR was performed to amplify six PABL group genes (16, 17) . A series of specific primers were used for the detection of DHA-1, CMY-2, MOX, ACC, EBC, FOX, TEM, SHV, and CTX-M (7, 16, 23, 27) (Table 1 ). The PCR products were purified with a QIAquick PCR purification kit (Qiagen, Hilden, Germany) and cloned into DH5␣. Plasmid DNA was prepared by using Qiagen columns and was sequenced on an ABI PRISM 377 automated sequencer (Applied Biosystems, Foster City, CA).
IEF. IEF was performed as described previously (9) . Crude beta-lactamase extracts were subjected to analytical IEF on an ampholine polyacrylamide gel (pH 3.5 to 9.5; Pharmacia, Uppsala, Sweden). Preparations from standard strains known to harbor TEM-12 (pI 5.25), TEM-10 (pI 5.6), TEM-29 (pI 6.1), SHV-1 (pI 7.6), and ACT-1 (pI 9) plasmid-mediated ␤-lactamases were used as controls. Beta-lactamases were visualized with a 0.2-mg/ml nitrocefin solution (Oxoid Ltd., Basingstoke, England). A 1 mM solution of potassium clavulanate and a 0.3 mM solution of cloxacilin were used to visualize general inhibitor characteristics.
DNA fingerprinting. Random amplified polymorphic DNA (RAPD) analysis was applied to type the PABL-producing isolates with the primer ERIC2. Amplified PCR products were separated using 1.5% agarose gels and visualized by UV transillumination. DNA fingerprints were compared by visual inspection. RAPD patterns were regarded as different if there were different bands on visual inspection (10, 12, 21) .
Conjugation. E. coli C600, with rifamycin resistance (Rif r ), was used as the recipient strain. Cultures of donor and recipient cells were grown to saturation, and 0.1 ml of each was added to the same medium (5 ml) and allowed to stand at 37°C for 2 h. The mixture was then incubated with shaking for 3 h, and 0.1-ml samples were streaked onto MacConkey agar containing 100 mg/liter rifampin and 10 mg/liter cefotaxime.
Southern hybridization. Southern blot hybridizations were performed by standard methods (22) with a bla CMY-2 -specific and bla DHA-1 -specific digoxigenin (DIG)-labeled probe. Briefly, purified plasmid DNA was transferred onto a positively charged nylon membrane (Millipore) by capillary action. DIG-labeled bla CMY-2 -specific and bla DHA-1 -specific detection probes were generated according to the directions of the manufacturer (Roche Diagnostics). After prehybridization, hybridization of the membrane with the denatured, DIG-labeled probe (25 ng/ml of hybridization solution) was done overnight at 65°C. The hybridized probes were immunodetected with anti-DIG-alkaline phosphatase.
Statistical analysis. All statistical tests were two-tailed 2 tests, and the results were considered statistically significant at a P value of Ͻ0.05. The data were stored and analyzed by using SPSS (version 12.0).
RESULTS
Three hundred twenty-seven (16.9%) of the 1,935 clinical isolates yielded cefoxitin zone diameters less than 18 mm (screen positive), 54 of which were demonstrated to harbor PABLs by multiplex PCR; 41 isolates carried bla genes of the DHA group, and 13 isolates carried genes belonging to the CIT group.
Two types of PABLs were detected by PCR with specific primers and confirmed as DHA-1 (41 isolates) and CMY-2 (13 isolates) by sequencing analysis. Each isolate produced one to four ␤-lactamases, with pI values of 5.4, 7.6, 8.2, 7.8, and 9.0. The pI 5.4 ␤-lactamase corresponds to the TEM-like enzyme (inhibited by clavulanate), and the pI 7.6 and 8.2 ␤-lactamases correspond to SHV-like and CTX-like enzymes (inhibited by clavulanate), respectively. The ␤-lactamases with pI values of 7.8 and 9.0 were inhibited by cloxacilin but not by clavulanate and were consistent with DHA-1 and CMY-2 enzymes, respectively.
Based on species, PABLs were detected in 30 (4.29%) of 699 K. pneumoniae, 23 (1.91%) of 1,203 E. coli, and 1 (3.03%) of 33 K. oxytoca isolates. The genotypes of PCR amplification showed that DHA-1 and CMY-2 were harbored by 29 and 1 of 30 PABLproducing K. pneumoniae isolates and 11 and 12 of the 23 E. coli isolates, respectively. The prevalence rate of DHA-1-producing K. pneumoniae was 7.54% in 2003, and this proportion significantly decreased, to 2.72%, in 2004 (P Ͻ 0.01) but was not significant between 2003 and 2005 (2.96%) ( Table 2 ). ERIC2 PCR was performed to investigate whether the prevalence of DHA-1-producing K. pneumoniae was due to nosocomial outbreaks of infections caused by epidemic strains. The 15 isolates of DHA-1-producing K. pneumoniae from 2003 had seven different patterns (Fig. 1) . Two of the DHA-1-producing K. pneumoniae isolates from 2004 displayed the same RAPD pattern. Only 5 of 13 DHA-1-producing E. coli strains showed one pattern (data not shown). Twenty-seven DHA-1-producing isolates and 10 CMY-2- producing isolates were positive for ESBL production according to phenotypic ESBL confirmatory tests (Table 3) . Based on species, 78.3% (18/23) of E. coli strains and 60% (18/30) of K. pneumoniae strains produced PABL and ESBL simultaneously. In order to determine the ESBL gene relatively exactly, we analyzed the beta-lactamases of these isolates by PCR experiments with a series of primers specific for bla TEM , bla SHV , and bla CTX-M . All 54 PABL-producing isolates harbored bla TEM -like genes. bla SHV -like and bla CTX-M -like genes were found in 37 and 29 of the 54 isolates, respectively. Thirtyseven of 41 DHA-1-producing isolates harbored bla SHV -like genes, and 20 of these 37 isolates harbored bla CTX-M -like genes simultaneously. Nine of 13 CMY-2-producing isolates harbored bla CTX-M -like genes. Four of 13 CMY-2-producing isolates transferred bla CMY-2 to transconjugants, 3 had bla CMY-2 alone, and 1 had bla CMY-2 and bla CTX-M . The Southern blot analysis further revealed that bla DHA-1 (data not shown) and bla CMY-2 were located on plasmids (Fig. 2) . The susceptibilities of the 54 isolates were as follows: piperacillin, 0%; cefazolin, 0%; cefotaxime, 13%; ceftazidime, 25.9%; cefepime, 53.7%; imipenem, 98%; and meropenem, 98%. The MICs and pI values of the isolates harboring CMY-2-type PABLs are given in Table 4 .
DISCUSSION
Plasmid-mediated class C ␤-lactamases have been discovered most frequently in naturally AmpC-negative species, such as K. pneumoniae, K. oxytoca, Salmonella spp., and Proteus mirabilis, and also in E. coli, which normally weakly expresses the chromosomal AmpC enzyme by gene duplication or mutation in the ampC promoter or attenuator, with consequent enhanced gene expression. Since CMY-1 was first reported (isolated from South Korea in 1989), over 40 types of PABLs have been reported worldwide. The prevalence of PABLs among clinical isolates differs depending on the countries and institutions. In China, though PABL (ACT-1 type) was first reported in 2002 (3), the true rate of occurrence of PABLs remains unknown. In this study, the prevalence rate (2.79%) of PABLs in Escherichia coli and Klebsiella spp. is similar to that in Korea (3.1%) but higher than that in the United States (1.2%) (4, 25) . The inducible PABL DHA-1 is the most prevalent PABL in China. DHA-1 is also the most prevalent PABL in other areas of Asia (25, 30) .
Based on species, 1.9% of E. coli and 4.3% of K. pneumoniae isolates harbored PABLs in this study. In Korea, the occurrence rates for these species are 1.5% and 5.4% (or 2.9%), respectively (24, 25) . But in the United States, they decreased to 1.6% (4) and 3.3% (13) due to a combination of clonal spread and horizontal transmission of plasmids (Fig. 3) . Because PABLs provided a broader spectrum of resistance than ESBLs and were not inhibited by commercially available inhibitors, the antimicrobial agents that could be used are limited. Previous studies suggested that cefepime might be effective for the treatment of infections caused by an AmpCproducing organism. However, in this study, only 53.7% (29 of 54) PABL producers were susceptible to cefepime. Song et al. reported that the association of PABLs with ESBLs may cause failure of treatment, and there is also a report indicating the high inoculum effect of cefepime in PABL-producing isolates (11, 20, 26) . Thirty-seven (68.5%) of the 54 PABL-producing isolates also produced an ESBL, which was confirmed by CLSI-recommended confirmatory tests. By the PCR method, 47 (87.0%) of the 54 isolates were detected to harbor bla CTXlike or bla SHV -like genes. Based on species, 93.3% (28/30) of K. pneumoniae and 78.3% (18/23) of E. coli isolates harbored beta-lactamase genes of AmpC and bla CTX -like or bla SHV -like genes simultaneously. This rate of K. pneumoniae is far higher than that in Korea (8.7%) but is lower than that in Japan (100%) (14, 24) . In this study, one isolate (no. 12404), which harbored bla CMY-2 , bla TEM -like, and bla CTX -like genes, was simultaneously resistant to imipenem and meropenem. Poirel et al. reported that one E. coli strain with CMY-2 and without outer membrane proteins OmpF and OmpC was resistant to carbapenem and other broad-spectrum cephalosporins (19) . The conjugation test of this isolate was not successful, and further research is in progress.
Southern blot hybridization revealed that the CMY-2 gene is located on plasmid. The different bands that hybridized to the CMY-2 probe, though the size of each band differed in each isolate, could presumably represent another gene that has homology to bla CMY-2 or partial or complete duplications of CMY-2. The CMY-2 ␤-lactamase was first described in 1990 (2) . It is the ancestor of the other C. freundii ampC alleles that have been found on plasmids since then (1). CMY-2 was detected not only in E. coli, K. pneumoniae, K. oxytoca, and P. mirabilis but also in Salmonella and Shigella (5, 8, 15) , the last two having caused an outbreak. CMY-2 is the most prevalent and geographically the most widely distributed PABL (18) . In China, the most prevalent type of PABL is DHA-1. The CMY-2 ␤-lactamase has not been previously reported to occur in China. In 2004, Guan et al. (6) reported a new CMY-type cephalosporinase which is 99% identical to the deduced amino acid sequences of CMY-2 and CMY-7. To the best of our knowledge, this is the first report of plasmid-mediated CMY-2-type AmpC ␤-lactamases in mainland China.
In conclusion, the prevalence rate of PABLs is 2.79% in Escherichia coli and Klebsiella spp. in this collection of isolates from a medical center in China. DHA-1 is the predominant PABL, and DHA-1-producing K. pneumoniae is the most prevalent bacterial species harboring PABLs. The results of this study reinforce the need for increasing concern for therapy for clinical infections caused by isolates that coproduce PABL and ESBL. This study also represents the first time that CMY-2 has been described to occur in China.
